(Boursier.com) — BIOSENIC, a company specializing in clinical trials in serious autoimmune and inflammatory diseases and cell therapy, will share for the first time post hoc data on its late clinical asset JTA-004 during the 2024 World Congress of Osteoarthritis Research Society International (OARSI). Post hoc analysis of a phase 3 study found that a single injection of JTA-004 was safe and effective for patients with a newly characterized severe inflammatory subtype of knee osteoarthritis.
The data will be presented by Yves Henrotin, Ph.D, professor at the University of Liège in Belgium (musculoSKeletal Innovative research Lab, mSKIL), Center for Interdisciplinary Research in Medicine, CIRM), as well as founder and chairman of the board of directors of Artialis, which carried out the analysis.
JTA-004 is an innovative intra-articular viscosupplement treatment for knee osteoarthritis, composed of hyaluronic acid, plasma proteins and clonidine. The post hoc analysis focuses on different subpopulations of patients with osteoarthritis, in data from a phase 3 trial (KOA-2) completed in 2019. The trial aimed to demonstrate that treatment with JTA-004 results in a reduction in the intensity of knee pain compared to saline or Synvisc-One, three months after injection, in subjects with symptomatic osteoarthritis of the knee.
Initial results obtained in a large group of patients representing several subtypes were inconclusive. However, BioSenic decided to reevaluate the data following the publication of a study1 that identified biomarkers to stratify osteoarthritis phenotypes, including a subtype of the disease characterized by systemic inflammation and the most common symptoms. serious. The conclusion of the post hoc analysis is that JTA-004 is safe and effective in successfully treating symptoms in this inflammatory subgroup.
©2024 Boursier.com